# Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

> **NCT01084057** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 56 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** ixabepilone
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01084057
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-17
- **Primary completion:** 2012-11-12
- **Final completion:** 2019-09-27
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01084057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01084057, "Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01084057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*